ClinicalTrials.gg
CompletedNCT01582308Updated May 30, 2017Results posted

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

A Phase 1 interventional study of Sitagliptin 100 mg and Saxagliptin 5 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
160th of 197
22 · median 102
Started
2012
with 15 others
Phase 1
23 of 198
none open now
Registered
116th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 160th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 23 in phase 1, and was the 116th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily dosing and vildagliptin after 5 days of twice daily dosing in participants with T2DM. The primary hypothesis is that following multiple daily dose administration to achieve steady-state drug concentrations, 100-mg sitagliptin will demonstrate greater DPP-4 inhibition at 24-hours after the final dose compared to 5-mg saxagliptin and 50-mg vildagliptin (once daily administration) in participants with T2DM. Each participant will receive all 5 treatments in randomized order. There will be a washout interval of at least 10 days between the last dose of study drug in one period and the first dose of study drug in the following period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female participants of must not be pregnant and agree to use (and/or have their partner use) two acceptable methods of beginning at least 2 weeks prior to administration of the first dose of study drug until at least 2 weeks after the last administration of study drug
  • has a between 18 and 43 kg/m\^2 inclusive
  • has a clinically confirmed diagnosis of T2DM
  • is not currently receiving any oral antihyperglycemic medications and has a screening visit (HbA1c) between 6.5% and 10% inclusive
  • must not have been previously treated with a DPP-4 inhibitor or glucagon-like peptide-1 analogs within 12 weeks of prestudy visit
  • has fasting plasma or serum glucose (FPG) ≤200 mg/dL (11.1 mmol/L) at screening and randomization
  • is a non-smoker or has not used nicotine or nicotine-containing products for at least approximately the last 6 months
  • is willing to follow the American Heart Association weight maintaining diet and exercise program or equivalent beginning 2 weeks prior to administration of first dose of study drug and throughout the study until the poststudy visit
  • agrees to refrain from the consumption of grapefruit and grapefruit juice for at least 2 weeks prior to the start of the study and throughout the study
  • agrees to refrain from the consumption of all fruit juices periodically throughout the study

Exclusion criteria

Exclusion Criteria:

  • is mentally or legally incapacitated, has significant emotional problems at the time of prestudy visit or expected during the conduct of the study or has a history of a psychiatric disorder over the last 5 years
  • has an estimated of ≤60 mL/min
  • has a history of stroke, chronic seizures, or major neurological disorder
  • has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases (with the exception of stable thyroid disease, T2DM and typical associated diseases such as hypertension and hyperlipidemia)
  • must not have been previously treated with any regimen that includes insulin (injected or inhaled) for at least 3 months
  • has a history of type 1 diabetes mellitus and/or history of ketoacidosis, or C peptide ≤0.8 ng/mL (≤0.26 nmol/L); or secondary forms of diabetes, acute metabolic diabetic complications or evidence of significant diabetic complications (i.e. retinopathy, neuropathy, nephropathy)
  • has a history of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease
  • is on a weight loss program and is not in the maintenance phase, or participant has been treated with a weight loss medication within 8 weeks of screening
  • anticipates the use of any new medication(s), including prescription and non-prescription drugs or herbal remedies beginning approximately 2 weeks prior to administration of the initial dose of study drug and throughout the study until the poststudy visit
  • anticipates any change in dose of current stable medications
  • has donated or lost 1 unit of blood within 4 weeks of the prestudy visit
  • has had major surgery within 30 days prior to screening or has planned major surgery
  • has a history of uncontrolled hypertension
  • is taking a medication which is not permitted in the study to treat a co-morbid condition, including but not limited to cytochrome P450 3A4/5 inhibitors and inducers, P-glycoprotein 1 inhibitors, and human organic anion transporter 3 inhibitors
  • consumes excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverage daily
  • has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
  • is currently a regular user (including "recreational use") of any illicit drugs or has a history of drug (including alcohol) abuse within approximately the past 6 months
  • is a nursing mother
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 2

    Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 3

    Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 4

    Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 5

    Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 6

    Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 7

    Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 8

    Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 9

    Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

  • Experimental
    Treatment Sequence 10

    Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5

    Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo

Interventions

  • Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

    Also known as: Januvia™

  • Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

    Also known as: Onglyza™

  • Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

    Also known as: Galvus™

  • Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.

    Also known as: Galvus™

  • DrugPlacebo

    Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.

06

What researchers measure

Primary outcomes

  1. Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough

    Percent inhibition of DPP-4 activity at 24 hours after the Day 5 morning dose (i.e., at trough) was determined by analysis of blood samples collected from the study participants.

    Time frame: 24 hours following the final morning dose on Day 5

Secondary outcomes

  1. Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr)

    AUC 0-24hr is the area under the plasma drug concentration-time curve calculated for the 24 hour interval after the Day 5 morning dose.

    Time frame: Predose (0 Hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20 and 24 hours after the morning dose on Day 5

  2. Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID

    AUC 0-12hr is the area under the plasma drug concentration-time curve calculated for the 12 hour interval after the Day 5 morning dose for the vildagliptin 50 mg BID dose only.

    Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8 and 12 hours after the morning dose on Day 5

  3. Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax)

    Measurement of the peak plasma drug concentration following the Day 5 morning dose.

    Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5

  4. Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax)

    Measurement of the time to the peak plasma drug concentration following the Day 5 morning dose.

    Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5

07

Results

Posted Jan 22, 2014

Participant flow

Each treatment sequence started with 2 participants in Period 1. In addition, there were 2 replacement participants; in treatment sequence 5, a participant who discontinued after period 1 (placebo treatment) was replaced and in treatment sequence 7, a participant who discontinued during period 1 (saxagliptin treatment) was replaced.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222323222
Completed2222322222
Not completed0000001000
Withdrew: Withdrawal by subject0000001000
10-day Washout Following Period 1
Participant flow — 10-day Washout Following Period 1
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222322222
Completed2222222222
Not completed0000100000
Withdrew: Physician decision0000100000
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222222222
Completed2222222222
Not completed0000000000
10-day Washout Following Period 2
Participant flow — 10-day Washout Following Period 2
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222222222
Completed2222222222
Not completed0000000000
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222222222
Completed2222222222
Not completed0000000000
10-day Washout Following Period 3
Participant flow — 10-day Washout Following Period 3
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222222222
Completed2222222222
Not completed0000000000
Period 4
Participant flow — Period 4
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started2222222222
Completed1222212221
Not completed1000010001
Withdrew: Physician decision1000010001
10-day Washout Following Period 4
Participant flow — 10-day Washout Following Period 4
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started1222212221
Completed1222212221
Not completed0000000000
Period 5
Participant flow — Period 5
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Treatment Sequence 6Treatment Sequence 7Treatment Sequence 8Treatment Sequence 9Treatment Sequence 10
Started1222212221
Completed1222212221
Not completed0000000000

Outcome measures

PrimaryPercent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough

Percent inhibition of DPP-4 activity at 24 hours after the Day 5 morning dose (i.e., at trough) was determined by analysis of blood samples collected from the study participants.

Time frame:
24 hours following the final morning dose on Day 5
Reported as:
Least squares mean · Percent inhibition
Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough
Percent inhibitionSitagliptin 100 mgSaxagliptin 5 mgVildagliptin 50 mgVildagliptin 50 mg BIDPlacebo
Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough91.73 (91.37 to 92.08)73.50 (66.56 to 79.00)28.88 (17.90 to 38.38)90.63 (88.93 to 92.06)3.49 (-0.66 to 7.48)
Statistical analysis
  • Sitagliptin 100 mg vs Saxagliptin 5 mg · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 18.24 · 90% CI 14.97 to 21.67
  • Sitagliptin 100 mg vs Vildagliptin 50 mg · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 62.86 · 90% CI 58.21 to 67.74
  • Sitagliptin 100 mg vs Vildagliptin 50 mg BID · Linear mixed effects model · p = 0.128 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 1.11 · 90% CI -0.10 to 2.33
  • Sitagliptin 100 mg vs Placebo · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 88.24 · 90% CI 85.77 to 90.76
  • Saxagliptin 5 mg vs Vildagliptin 50 mg · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 44.62 · 90% CI 34.51 to 55.23
  • Saxagliptin 5 mg vs Vildagliptin 50 mg BID · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: -17.13 · 90% CI -21.21 to -13.25
  • Saxagliptin 5 mg vs Placebo · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 70.00 · 90% CI 58.46 to 82.20
  • Vildagliptin 50 mg vs Vildagliptin 50 mg BID · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: -61.75 · 90% CI -68.76 to -55.18
  • Vildagliptin 50 mg vs Placebo · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 25.38 · 90% CI 15.37 to 35.48
  • Vildagliptin 50 mg BID vs Placebo · Linear mixed effects model · p = <.001 (P-value of between-treatment comparison of percent inhibition of DPP-4 activity.) · Least squares mean difference: 87.13 · 90% CI 80.06 to 94.61
SecondaryPharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr)

AUC 0-24hr is the area under the plasma drug concentration-time curve calculated for the 24 hour interval after the Day 5 morning dose.

Time frame:
Predose (0 Hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20 and 24 hours after the morning dose on Day 5
Reported as:
Geometric mean · nM*hr
Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr)
nM*hrSitagliptin 100 mgSaxagliptin 5 mgVildagliptin 50 mgVildagliptin 50 mg BID
Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr)7070 ± 25.1370 ± 253100 ± 276600 ± 26.3
SecondaryPharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID

AUC 0-12hr is the area under the plasma drug concentration-time curve calculated for the 12 hour interval after the Day 5 morning dose for the vildagliptin 50 mg BID dose only.

Time frame:
Predose (0 hours) and 0.5, 1, 2, 4, 8 and 12 hours after the morning dose on Day 5
Reported as:
Geometric mean · nM*hr
Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID
nM*hrVildagliptin 50 mg BID
Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID3720 ± 28.9
SecondaryPharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax)

Measurement of the peak plasma drug concentration following the Day 5 morning dose.

Time frame:
Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5
Reported as:
Geometric mean · nM
Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax)
nMSitagliptin 100 mgSaxagliptin 5 mgVildagliptin 50 mgVildagliptin 50 mg BID
Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax)724 ± 31.388.8 ± 25.2586 ± 37759 ± 34.7
SecondaryPharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax)

Measurement of the time to the peak plasma drug concentration following the Day 5 morning dose.

Time frame:
Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5
Reported as:
Median · hr
Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax)
hrSitagliptin 100 mgSaxagliptin 5 mgVildagliptin 50 mgVildagliptin 50 mg BID
Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax)4 (0.5 to 8)1 (0.5 to 2)1 (0.5 to 8)1 (0.5 to 4)

Adverse events

Collected over Through approximately 14 days following the last dose of study drug in Period 5. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg—0/20 (0%)1/20 (5%)
Saxagliptin 5 mg—0/21 (0%)4/21 (19%)
Vildagliptin 50 mg—0/18 (0%)1/18 (5.6%)
Vildagliptin 50 mg BID—0/19 (0%)1/19 (5.3%)
Placebo—0/21 (0%)0/21 (0%)
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgSaxagliptin 5 mgVildagliptin 50 mgVildagliptin 50 mg BIDPlacebo
InfluenzaInfections and infestations0/202/210/180/190/21
HeadacheNervous system disorders1/202/211/181/190/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Enrolled Participants
<=18 years0
Between 18 and 65 years22
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Participants
Female12
Male10
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB, Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 2013 Dec;4(2):431-42. doi: 10.1007/s13300-013-0045-8. Epub 2013 Oct 26. PubMed 24163113 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Dec 2012, 5 months.

Results were first posted in Jan 2014, 1 year 1 month after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 5 months is close to that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2012
First posted
Apr 20, 2012
StartActual
Jun 21, 2012
Primary completionActual
Dec 4, 2012
CompletionActual
Dec 14, 2012
Results first posted
Jan 22, 2014
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01582308
Responsible party
Sponsor
First posted
Apr 20, 2012
Start date
Jun 21, 2012
Primary completion
Dec 4, 2012
Completion
Dec 14, 2012
Results posted
Jan 22, 2014
Last update
May 30, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Saxagliptin · Vildagliptin

Start the discussion